Skye Bioscience, Inc. – OTC:SKYE
Skye Bioscience stock price today
$3.25
+0.79
+32.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Skye Bioscience stock price monthly change
-61.80%
month
Skye Bioscience stock price quarterly change
-61.80%
quarter
Skye Bioscience stock price yearly change
-3.53%
year
Skye Bioscience key metrics
Market Cap | 38.08M |
Enterprise value | 7.71M |
P/E | -0.4 |
EV/Sales | N/A |
EV/EBITDA | -0.31 |
Price/Sales | N/A |
Price/Book | -2.95 |
PEG ratio | N/A |
EPS | -4.51 |
Revenue | N/A |
EBITDA | -16.13M |
Income | -37.49M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSkye Bioscience stock price history
Skye Bioscience stock forecast
Skye Bioscience financial statements
| Jun 2023 | 0 | -3.11M | |
|---|---|---|---|
| Sep 2023 | 0 | -24.94M | |
| Dec 2023 | 191.76K | -4.41M | -2304.93% |
| Mar 2024 | 0 | -5.01M |
| 2025 | 0 | -33.31M | |
|---|---|---|---|
| 2026 | 0 | -44.26M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2235944 | 10.02M | 448.36% |
|---|---|---|---|
| Sep 2023 | 15604330 | 13.90M | 89.14% |
| Dec 2023 | 11940411 | 14.07M | 117.85% |
| Mar 2024 | 94835276 | 15.95M | 16.82% |
| Jun 2023 | -1.99M | 0 | -123.41K |
|---|---|---|---|
| Sep 2023 | -4.05M | 1.07M | 16.63M |
| Dec 2023 | -3.84M | -7.01K | -22.65K |
| Mar 2024 | -4.70M | 1.14M | 85.65M |
Skye Bioscience alternative data
| Aug 2023 | 11 |
|---|---|
| Sep 2023 | 11 |
| Oct 2023 | 11 |
| Nov 2023 | 11 |
| Dec 2023 | 11 |
| Jan 2024 | 11 |
| Feb 2024 | 11 |
| Mar 2024 | 11 |
| Apr 2024 | 11 |
| May 2024 | 11 |
| Jun 2024 | 11 |
| Jul 2024 | 11 |
Skye Bioscience other data
0.00%
-0.00%
of SKYE is owned by hedge funds
11.9K
+0
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 5206074 | 0 |
| Mar 2024 | 450000 | 0 |
| Sep 2024 | 0 | 532674 |
| Nov 2024 | 0 | 232431 |
-
What's the price of Skye Bioscience stock today?
One share of Skye Bioscience stock can currently be purchased for approximately $3.25.
-
When is Skye Bioscience's next earnings date?
Unfortunately, Skye Bioscience's (SKYE) next earnings date is currently unknown.
-
Does Skye Bioscience pay dividends?
No, Skye Bioscience does not pay dividends.
-
How much money does Skye Bioscience make?
Skye Bioscience has a market capitalization of 38.08M.
-
What is Skye Bioscience's stock symbol?
Skye Bioscience, Inc. is traded on the OTC under the ticker symbol "SKYE".
-
What is Skye Bioscience's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Skye Bioscience?
Shares of Skye Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Skye Bioscience have?
As Jul 2024, Skye Bioscience employs 11 workers.
-
When Skye Bioscience went public?
Skye Bioscience, Inc. is publicly traded company for more then 4 years since IPO on 1 Jun 2021.
-
What is Skye Bioscience's official website?
The official website for Skye Bioscience is skyebioscience.com.
-
Where are Skye Bioscience's headquarters?
Skye Bioscience is headquartered at 5910 Pacific Center Boulevard, San Diego, CA.
-
How can i contact Skye Bioscience?
Skye Bioscience's mailing address is 5910 Pacific Center Boulevard, San Diego, CA and company can be reached via phone at +94 94809051.
Skye Bioscience company profile:
Skye Bioscience, Inc.
skyebioscience.comExchange:
OTC
Full time employees:
9
Industry:
Biotechnology
Sector:
Healthcare
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
5910 Pacific Center Boulevard
San Diego, CA 92130
San Diego, CA 92130
CIK: 0001516551
:
:
